Skip to main content

BRIEF RESEARCH REPORT article

Front. Hematol.
Sec. Immunobiology and Immunotherapy
Volume 3 - 2024 | doi: 10.3389/frhem.2024.1346627
This article is part of the Research Topic Rising Stars in Immunobiology and Immunotherapy 2023 View all articles

Novel cryopreservation medium for enhanced stability of T cells at -80 °C

Provisionally accepted
Wenxuan Zhou Wenxuan Zhou 1Chen Wang Chen Wang 1Yao Shi Yao Shi 1Yi Pan Yi Pan 1Xiaduo Meng Xiaduo Meng 1Xunlei Kang Xunlei Kang 1,2,3*Xu Han Xu Han 4,5*
  • 1 Center for Precision Medicine, School of Medicine, University of Missouri, Columbia, United States
  • 2 Division of Hematology and Oncology, Department of Medicine, School of Medicine, University of Missouri, Columbia, Missouri, United States
  • 3 Ellis Fischel Cancer Center, School of Medicine, University of Missouri, Columbia, Missouri, United States
  • 4 CryoCrate LLC, Columbia, United States
  • 5 Wake Forest Institute for Regenerative Medicine, School of Medicine, Wake Forest University, Winston-Salem, North Carolina, United States

The final, formatted version of the article will be published soon.

    The increasing demand for immune cell applications, both in clinical settings and research laboratories, has highlighted the critical need for cryopreservation (banking) methods for T cells. While conventional techniques like liquid nitrogen freezing remain prevalent, they pose significant challenges such as high equipment costs, safety considerations, and logistical hurdles in transportation. Our cryopreservation medium, C80EZ ® , represents a novel approach, leveraging biocompatible polysaccharides as cryoprotectants to enable safe storage at -80°C. This paper presents a comprehensive series of tests assessing the effectiveness of C80EZ ® in shielding T cells from the detrimental effects of cryopreservation. Importantly, our findings demonstrate that C80EZ ® not only ensures the survival of T cells, with a particular emphasis on preserving CD8 + subsets, but also maintains their critical function in targeting and eliminating cancer cells.

    Keywords: Cryopreservation, Immunotherapy, T cell, DMSO, C80EZ

    Received: 29 Nov 2023; Accepted: 22 May 2024.

    Copyright: © 2024 Zhou, Wang, Shi, Pan, Meng, Kang and Han. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Xunlei Kang, Center for Precision Medicine, School of Medicine, University of Missouri, Columbia, United States
    Xu Han, CryoCrate LLC, Columbia, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.